Works by LoRusso, Patricia
Results: 136
A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administration.
- Published in:
- 2005
- By:
- Publication type:
- journal article
Response.
- Published in:
- 2013
- By:
- Publication type:
- Letter
RE: Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials.
- Published in:
- 2013
- By:
- Publication type:
- Letter
Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2012, v. 104, n. 24, p. 1860, doi. 10.1093/jnci/djs439
- By:
- Publication type:
- Article
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma.
- Published in:
- Pigment Cell & Melanoma Research, 2020, v. 33, n. 3, p. 390, doi. 10.1111/pcmr.12847
- By:
- Publication type:
- Article
Dogs Are More Sensitive to Antagonists of Inhibitor of Apoptosis Proteins Than Rats and Humans: A Translational Toxicokinetic/Toxicodynamic Analysis.
- Published in:
- Toxicological Sciences, 2012, v. 130, n. 1, p. 205, doi. 10.1093/toxsci/kfs235
- By:
- Publication type:
- Article
Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal.
- Published in:
- Cancer Investigation, 2023, v. 41, n. 7, p. 646, doi. 10.1080/07357907.2023.2242957
- By:
- Publication type:
- Article
Quantitative Profiling of Oncometabolites in Frozen and Formalin-Fixed Paraffin-Embedded Tissue Specimens by Liquid Chromatography Coupled with Tandem Mass Spectrometry.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-47669-5
- By:
- Publication type:
- Article
Capecitabine and PPE Syndrome: A Case Report.
- Published in:
- Breast Journal, 2003, v. 9, n. 1, p. 64, doi. 10.1046/j.1524-4741.2003.09119.x
- By:
- Publication type:
- Article
Review: Targeting the Hedgehog pathway in cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2010, v. 2, n. 4, p. 237, doi. 10.1177/1758834010366430
- By:
- Publication type:
- Article
Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
- Published in:
- British Journal of Cancer, 2018, v. 119, n. 9, p. 1086, doi. 10.1038/s41416-018-0235-2
- By:
- Publication type:
- Article
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
- Published in:
- British Journal of Cancer, 2018, v. 118, n. 2, p. 153, doi. 10.1038/bjc.2017.327
- By:
- Publication type:
- Article
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
- Published in:
- 2018
- By:
- Publication type:
- corrected article
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Analysis of Lung Cancer Patients Enrolled in CTEP (Cancer Therapy Evaluation Program)-Sponsored Phase I Trials.
- Published in:
- Clinical Lung Cancer, 2011, v. 12, n. 4, p. 218, doi. 10.1016/j.cllc.2011.03.022
- By:
- Publication type:
- Article
A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
The Role of Phosphoinositide 3-Kinase in Breast Cancer: An Overview.
- Published in:
- Clinical Breast Cancer, 2010, v. 10, p. S56, doi. 10.3816/CBC.2010.s.012
- By:
- Publication type:
- Article
Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors.
- Published in:
- 2025
- By:
- Publication type:
- Correction Notice
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors.
- Published in:
- Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2024.1376551
- By:
- Publication type:
- Article
Network Rewiring in Cancer: Applications to Melanoma Cell Lines and the Cancer Genome Atlas Patients.
- Published in:
- Frontiers in Genetics, 2018, p. N.PAG, doi. 10.3389/fgene.2018.00228
- By:
- Publication type:
- Article
A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
- Published in:
- Cancer (0008543X), 2005, v. 103, n. 12, p. 2584
- By:
- Publication type:
- Article
Mammalian Target of Rapamycin as a Rational Therapeutic Target for Breast Cancer Treatment.
- Published in:
- Oncology, 2012, v. 84, n. 1, p. 43, doi. 10.1159/000343063
- By:
- Publication type:
- Article
Quantifying the impact of the COVID-19 pandemic on cancer center clinical trial operations.
- Published in:
- JNCI Cancer Spectrum, 2023, v. 7, n. 4, p. 1, doi. 10.1093/jncics/pkad048
- By:
- Publication type:
- Article
First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
- Published in:
- Journal of Hematology & Oncology, 2016, v. 9, p. 1, doi. 10.1186/s13045-016-0254-5
- By:
- Publication type:
- Article
Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer.
- Published in:
- PLoS ONE, 2015, v. 10, n. 3, p. 1, doi. 10.1371/journal.pone.0119614
- By:
- Publication type:
- Article
Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 1, p. 20, doi. 10.1002/jcph.1275
- By:
- Publication type:
- Article
Integrating Dynamic Positron Emission Tomography and Conventional Pharmacokinetic Studies to Delineate Plasma and Tumor Pharmacokinetics of FAU, a Prodrug Bioactivated by Thymidylate Synthase.
- Published in:
- Journal of Clinical Pharmacology, 2016, v. 56, n. 11, p. 1433, doi. 10.1002/jcph.751
- By:
- Publication type:
- Article
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.
- Published in:
- Journal of Clinical Pharmacology, 2015, v. 55, n. 4, p. 392, doi. 10.1002/jcph.437
- By:
- Publication type:
- Article
Evaluation of the Effects of Food on the Single-Dose Pharmacokinetics of Trametinib, a First-in-Class MEK Inhibitor, in Patients with Cancer.
- Published in:
- Journal of Clinical Pharmacology, 2013, v. 53, n. 9, p. 946, doi. 10.1002/jcph.115
- By:
- Publication type:
- Article
Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer.
- Published in:
- Journal of Clinical Pharmacology, 2012, v. 52, n. 5, p. 691, doi. 10.1177/0091270011403742
- By:
- Publication type:
- Article
Clinical Pharmacokinetics and Exposure- Toxicity Relationship of a Folate-Vinca Alkaloid Conjugate EC145 in Cancer Patients.
- Published in:
- Journal of Clinical Pharmacology, 2009, v. 49, n. 12, p. 1467, doi. 10.1177/0091270009339740
- By:
- Publication type:
- Article
Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases.
- Published in:
- Journal of Clinical Pharmacology, 2002, v. 42, n. 11, p. 1228, doi. 10.1177/0091270002238765
- By:
- Publication type:
- Article
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 4, p. 799, doi. 10.1002/cncr.27790
- By:
- Publication type:
- Article
Improving Precision Oncology through Better Designs and Reporting of Biomarker-Driven Randomized Clinical Trials.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 2, p. 122, doi. 10.1093/jnci/djac212
- By:
- Publication type:
- Article
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1376551
- By:
- Publication type:
- Article
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.
- Published in:
- Thyroid, 2020, v. 30, n. 9, p. 1254, doi. 10.1089/thy.2019.0269
- By:
- Publication type:
- Article
Identifying treatment options for BRAF<sup>V600</sup> wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.
- Published in:
- PLoS ONE, 2021, v. 16, n. 4, p. 1, doi. 10.1371/journal.pone.0248097
- By:
- Publication type:
- Article
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report.
- Published in:
- 2011
- By:
- Publication type:
- Report
Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregivers.
- Published in:
- Psycho-Oncology, 2013, v. 22, n. 3, p. 555, doi. 10.1002/pon.3036
- By:
- Publication type:
- Article
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 1, p. 107, doi. 10.1002/cpdd.575
- By:
- Publication type:
- Article
Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.
- Published in:
- OncoTargets & Therapy, 2024, v. 17, p. 267, doi. 10.2147/OTT.S440979
- By:
- Publication type:
- Article
Qualitative Analysis of the Experience of Mental Fatigue of Family Caregivers of Patients With Cancer in Phase I Trials.
- Published in:
- Oncology Nursing Forum, 2016, v. 43, n. 4, p. E153, doi. 10.1188/16.ONF.E153-E160
- By:
- Publication type:
- Article
Vascular targeting agents.
- Published in:
- Current Oncology Reports, 2004, v. 6, n. 2, p. 103, doi. 10.1007/s11912-004-0021-6
- By:
- Publication type:
- Article